NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Not true. Both have been associated with solid tumors.

From the current 10-K:

The Company’s lead product, DCVax®-L, is designed to treat solid tumor cancers in which the tumor can be surgically removed. This product in an ongoing Phase III trial for newly diagnosed Glioblastome multiforme (GBM). 331 patients have been enrolled in the trial, and enrollment is closed. The Company is also working on preparations for Phase II trials of DCVax-L for other indications.

The only clear wording difference they have used in the last several years is "operable" vs "in-operable". -L needs some tumor mass for manufacturing, so requires an operation.

The presentation would likely be on both. But that does not imply there need be any new data presented on either or both.